معرفی
Catherine Viscoli, PhD, is a Senior Research Scientist at Yale School of Medicine, affiliated with the Department of General Internal Medicine (primary) and Neurology (secondary). She holds roles in the Center for Brain & Mind Health and has contributed to translational research initiatives such as the Insulin Resistance Intervention after Stroke (IRIS) trial. Her research focuses on stroke prevention, diabetes management, and cardiovascular health, emphasizing clinical trial design, drug efficacy, and patient adherence. Viscoli has collaborated extensively with key figures like Dr. Walter Kernan and Dr. Lawrence Young, and her work has addressed metabolic syndrome impacts, insulin resistance risks, and neurological outcomes in stroke patients.
Education: PhD from Yale University (1990), MPhil in Economics from Yale (1983), BA in Economics from University of California, San Diego (1976). These interdisciplinary credentials underpin her quantitative approaches to medical research.
Her research interests combine clinical epidemiology with translational medicine, particularly investigating how metabolic factors influence vascular and neurological diseases. She has pioneered scoring systems to optimize therapies like pioglitazone while balancing risks such as fracture and heart failure. Recent work highlights silent myocardial infarction as a stroke recurrence predictor and disability’s role in stroke prevention trials.
Notable grants include a $33 million NIH award for the IRIS trial (2001). Her publications span stroke recurrence analysis, drug adherence challenges, and metabolic syndrome’s broader implications. She advocates for robust data archiving practices, as seen in her 2018 JCE response paper.
Labs/Teams: Core member of the IRIS Trial Investigators team, collaborating with multidisciplinary groups across neurology, cardiology, and endocrinology departments.
